Market Place
Sourcing Support
Apotex Launches First Generic Dasatinib Tablets in the United States
04 Sep 2024 //
PR NEWSWIRE
Novartis Scemblix ph III data first to show superior efficacy tolerability
03 Jun 2024 //
PHARMABIZ
Xspray Ppi Tki Cml Bioavailability: Negative Dasatinib Effects Asco Data
23 May 2024 //
BUSINESSWIRE
Teva`s Generic Dasatinib Receives Approval in the U.S.
06 Dec 2023 //
FDA
Teva Pharma Generic Dasatinib Receives Tentative Approval in US
01 Jul 2022 //
FDA
Accord Healthcare Dasatinib Receives Approval in Europe
10 Jun 2022 //
EMA
Alembic`s Generic Dasatinib Receives Approval in the U.S.
09 Jun 2022 //
FDA
Bristol-Myers Sues XSpray to Block Copies of Blockbuster Sprycel
25 Feb 2022 //
BLOOMBERG LAW
Health Canada Issues Recall of Reddy-Dasatinib: out of specification
02 Feb 2022 //
HEALTH CANADA
ICR researchers find drug combination to treat brain cancer in children
08 Nov 2021 //
PHARMACEUTICAL-TECHNOLOGY
Xspray reports positive results from a study with dasatinib during omeprazole
30 Dec 2020 //
PRESS RELEASE
Shilpa Medicare launches branded generic anticancer drug Dasatinib
23 Apr 2020 //
PHARMABIZ
Dr Reddy`s launches generic cancer drug in India
12 Apr 2020 //
MONEYCONTROL
Marrying CRISPR with immuno-oncology to defeat remote tumors
14 Oct 2019 //
FIERCE BIOTECH
EC OKs expanded use for Bristol-Myers` Sprycel
11 Feb 2019 //
SEEKING ALPHA
Sprycel combo gets FDA approval
03 Jan 2019 //
PHARMA TIMES
Bristol-Myers Squibb’s Sprycel (dasatinib) Tablets Approved
03 Jan 2019 //
BUSINESSWIRE
EMA Assessmt & Procedural Steps for Incyte`s Iclusig (ponatinib)
10 Oct 2018 //
EMA
EMA Assessment of Incyte Biosciences` Iclusig (ponatinib) & Procedural steps
10 Oct 2018 //
EMA
Xspray Pharma announces +ve data from clinical bioE study with HyNap-Dasa
11 Sep 2018 //
PHARMABIZ
Xspray Pharma Announces +ve Clinical Data for Candidate HyNap-Dasa
10 Sep 2018 //
PR NEWSWIRE
FDA Accepts Bristol-Myers Squibb’s Application for Sprycel
01 Sep 2018 //
RDMAG
EC approves expanded indication for Sprycel
06 Jul 2018 //
PHARMA LETTER
AZ’ lung cancer drug Tagrisso backed for first-line use
30 Apr 2018 //
PHARMA TIMES
U.S. Food and Drug Administration Expands Approval of Sprycel® (dasatinib)
10 Nov 2017 //
BUSINESSWIRE
Drug Helps Some Kids With Rare Type of Leukemia
05 Jun 2017 //
WEBMD
CML patients in England win access to Incyte’s Iclusig
03 May 2017 //
FIERCE BIOTECH
Global move against Roche brings focus back on cancer drug prices
16 Feb 2017 //
THE HINDU BUSINESS LINE
Bristol`s earnings at risk as court shuts down Sprycel patent in Europe
03 Feb 2017 //
FIERCE PHARMA
NICE backs BMS leukaemia drug Sprycel
21 Nov 2016 //
PMLIVE
NICE approves three quarters of CDF group 1 drugs
18 Nov 2016 //
PHARMATIMES
NICE approves three quarters of CDF drugs for routine NHS use
17 Nov 2016 //
EUROPEAN PHARMACEUTICAL
Roche, Bristol-Myers cut cancer drug prices to win UK approval
16 Nov 2016 //
REUTERS
BCR-ABL Tyrosine Kinase Inhibitors - Risk of Hepatitis B Reactivation
06 May 2016 //
HEALTH CANADA
Health Canada Require Updated Warning on Gleevec Labeling for Brand and Generics
05 May 2016 //
TWOFOUR INSIGHT
BCR-ABL Tyrosine Kinase Inhibitors
04 May 2016 //
HEALTH CANADA
Two Indian generics makers end battle to copy drugs amid patent debate
13 Apr 2016 //
REUTERS
Medicine to treat cancer wins indication for leukemia
17 Mar 2016 //
ANVISA
US FDA approves product labelling update for Sprycel to include efficacy and safety data
16 Aug 2015 //
PHARMABIZ
Indian court upholds BMS Sprycel patent, but list of challengers grows
08 Jul 2015 //
FIERCE PHARMA ASIA
Delhi High Court upholds BMS’ patent for cancer drug Dasatinib
05 Jul 2015 //
THE ECONOMIC TIMES
Attix Pharmaceuticals Recalls Hundreds of APIs From the U.S.
02 May 2015 //
FIERCE PHARMA MFG
Compulsory Licensing A Recognised Instrument Says WIPO Chief Francis Gurry
15 Jan 2015 //
THE ECONOMIC TIMES
